DBDraurio Barreira

Draurio Barreira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Draurio Barreira has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Frequency of macrolide resistance-associated mutations in Mycoplasma genitalium: a multicenter molecular analysis based in Brazil

    by Fernando Hartmann Barazzetti, Marcos André Schörner, Vilmar Benetti Filho, Henrique Borges da Silva Grisard, Julia Kinetz Wachter, Jéssica Motta Martins, Christinni Machado Venturi, Pâmela Cristina Gaspar, Angélica Espinosa Miranda, Dráurio Barreira, et al.

    Mycoplasma genitalium is an emerging sexually transmitted pathogen with increasing antimicrobial resistance worldwide. In Brazil, molecular testing for M. genitalium and resistance-associated mutations is not routinely available, and national data remain scarce. We analyzed 118 M. genitalium-positive urethral and vaginal swab samples collected between 2018 and 2023 from sites across all five Brazilian geographic regions. PCR amplification and sequencing of 23S rRNA, parC, and gyrA identified macrolide and fluoroquinolone resistance-associated mutations. Among 79 samples successfully sequenced for 23S rRNA, 40.5% harbored macrolide resistance-associated mutations (A2058G, A2059G, or A2058T) detected in samples from all five regions at different frequencies. A total of 6.1% of sequenced samples presented parC mutations, including two with combined 23S rRNA and parC mutations. No resistance-associated mutations were detected in gyrA. While resistance-associated mutations occurred in both symptomatic men and pregnant women, these findings are not representative estimates for the Brazilian population since the study used convenience samples from two distinct surveillance populations. Nonetheless, they provide multicenter molecular data that may inform future surveillance, diagnostic strategies, antimicrobial stewardship, and resistance-guided management of M. genitalium in Brazil.

  • Open Access

    Price as a challenge to the sustainability of the universal access policy to antiretrovirals in SUS: the case of dolutegravir

    by Luciana de Melo Nunes Lopes, Carolinne Thays Scopel, Ronaldo Campos Hallal, Gustavo Luís Meffe Andreoli, Draurio Barreira, Marcela Vieira Freire, Francisco Alisson Paula de França

    The price of antiretrovirals (ARVs) continues to be a challenge to guarantee universal, comprehensive, and equitable pharmaceutical services. This article aimed to analyze the acquisition of the most widely used ARV in Brazil, comparing national and international prices. Our study conducted a documentary analysis of the history of the national procurement of dolutegravir (DTG) from 2017 to 2023. The price comparison was based on reports from the Clinton Health Access Initiative (CHAI), considering exchange rate and inflation variations. In 2022, generic versions from Farmanguinhos and Lafepe were distributed, but a patent barrier restricted the procurement from Lafepe. A major difference was found between national and international prices, even with the entry of generics into the Brazilian market; in 2023, the price of international generics was almost 12 times lower than that of the national procurement. The DTG case highlights the importance of monitoring prices, patent barriers, and local production, and of becoming familiar with the structure of production costs in order to negotiate fair prices and ensure the sustainability of the national pharmaceutical assistance policy.

  • Open Access

    Preço como um desafio à sustentabilidade da política de acesso universal a antirretrovirais no SUS: o caso dolutegravir

    by Luciana de Melo Nunes Lopes, Carolinne Thays Scopel, Ronaldo Campos Hallal, Gustavo Luís Meffe Andreoli, Draurio Barreira, Marcela Vieira Freire, Francisco Alisson Paula de França

    Resumo O preço dos antirretrovirais (ARV) continua sendo um desafio para a garantia da assistência farmacêutica universal, integral e igualitária. O artigo teve como objetivo analisar a aquisição do ARV mais utilizado atualmente no Brasil, comparando preços nacionais e internacionais. Foi realizada análise documental do histórico de aquisição nacional do dolutegravir (DTG) entre 2017 e 2023. A comparação de preços baseou-se em relatórios da Clinton Health Access Initiative (CHAI), considerando variações cambiais e da inflação. Em 2022, versões genéricas de Farmanguinhos e Lafepe foram distribuídas, mas uma barreira patentária restringiu a aquisição junto ao Lafepe. Houve grande diferença entre preços nacionais e internacionais, mesmo com a entrada de genéricos no mercado brasileiro: em 2023, o preço de genéricos internacionais foi quase 12 vezes menor que o de aquisição nacional. O caso do DTG evidencia a importância do monitoramento dos preços, das barreiras patentárias, da produção local e do conhecimento da estrutura dos custos de produção para a negociação de preços justos e garantia da sustentabilidade da política nacional de assistência farmacêutica.

  • Open Access

    The BRICS Partnership for the Elimination of Socially Determined Diseases: a multilateral agenda to health equity

    by Draurio Barreira Cravo Neto, Marilia Santini de Oliveira, Silene Lima Dourado Ximenes Santos, Sarah Maria Soares Fernandes Bayma, Douglas Oliveira Carmo Lima, Fernanda Manara Whately Paiva, Thania Regina Fernandes Arruda, Natiela Beatriz de Oliveira, Ana Julia Silva e Alves, Virginia Kagure Wachira, et al.

    The creation of the BRICS Partnership for the Elimination of Socially Determined Diseases marks a pivotal step in positioning the social determinants of health at the forefront of global public policy and collective action. Socially determined diseases shaped by poverty, inequality, inadequate sanitation, and limited access to services, remain significant public health challenges across BRICS nations. Despite substantial progress in science, technology, and health system strengthening, global targets for disease elimination and reduction remain off track due to persistent financial gaps, fragmented programs, and insufficient multisectoral coordination. In this context, BRICS countries, representing nearly half of the world’s population, are uniquely positioned to drive transformative change by integrating health equity principles into national and international agendas. This manuscript describes the technical and political process that led to the formulation of the BRICS Partnership, culminating in its endorsement at the BRICS Leaders’ Meeting. The Partnership outlines five strategic objectives focused on strengthening resilient health systems, advancing intersectoral action, expanding research and innovation, securing sustainable financing, and aligning global positions to accelerate progress toward disease elimination. The initiative offers a comprehensive framework that addresses both disease-specific challenges and the broader structural drivers of inequity. The BRICS Partnership thus emerges as a global model of how collaboration, scientific advancement, multilateralism, and social justice can converge to accelerate the elimination, control, or reduction of socially determined diseases and promote a healthier, more equitable future.


  • Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium and risk factors among pregnant women in Brazil: Results from the national molecular diagnosis implementation project

    by Angélica Espinosa Miranda, Pâmela Cristina Gaspar, Marcos André Schörner, Fernando Hartmann Barazzetti, Guilherme Borges Dias, Alisson Bigolin, Ana Roberta Pati Pascom, Dráurio Barreira, Maria Luiza Bazzo, Brazilian Surveillance for STIs in Pregnant Women Group

    Background: Sexually transmitted infections (STIs) are a public health problem. The aim of the present study was to assess the prevalence and risk factors associated with at least one STI (Chlamydia trachomatis [CT], Neisseria gonorrhoeae [NG], Trichomonas vaginalis [TV], and Mycoplasma genitalium [MG]) in Brazil.Methods: A cross‐sectional study was conducted using secondary data from the pilot implementation of the National Service for molecular diagnosis of CT, NG, TV, and MG in pregnancy. We obtained Ministry of Health surveillance data from the implementation project. Data encompassing pregnant women aged 15–49 years from public antenatal clinics in Brazil in 2022 were included.Results: A total of 2728 data of pregnant women were analyzed. The prevalence of at least one infection was 21.0% (573), with the highest prevalence in the Southeast region (23.3%) and the lowest in the Center‐West region (15.4%). The prevalence of CT was 9.9% (270), NG 0.6% (16), TV 6.7% (184), and MG 7.8% (212). Factors associated with any infection were from 15 to 24 years (AOR = 1.93; 95% CI: 1.58–2.35); reported family income up to US$400 (AOR = 1.79; 95% CI: 1.03–3.34); declared not living maritally with their partners (AOR = 1.90, 95% CI: 1.52–2.37) and had more than one sexual partner in their lifetime (AOR = 2.09, 95% CI: 1.55–2.86).Conclusion: This study showed a high prevalence of at least one STI among pregnant women in Brazil, particularly among younger women. It also provides up‐to‐date national data on CT, NG, TV, and MG infections in this population. These findings underscore the importance of enhancing access to STI screening for young pregnant women within the Brazilian public health system.


  • Open Access

    Rede nacional de testes moleculares para detecção de Chlamydia trachomatis e Neisseria gonorrhoeae: experiência de implantação-piloto no Brasil

    by Pâmela Cristina Gaspar, Angélica Espinosa Miranda, Alisson Bigolin, Amanda Alencar Cabral Morais, Mayra Gonçalves Aragón, José Athayde Vasconcelos Morais, José Boullosa Alonso Neto, Leonor Henriette de Lannoy, Mauro Niskier Sanchez, Draurio Barreira Cravo Neto, et al.

    O objetivo deste estudo foi conhecer a opinião dos profissionais participantes da implantação-piloto de testes moleculares para detecção de Chlamydia trachomatis e Neisseria gonorrhoeae no Sistema Único de Saúde (SUS). Determinou-se a taxa de detecção de C. trachomatis e/ou N. gonorrhoeae e os fatores associados à infecção. A estratégia contou com laboratórios pertencentes à rede de carga viral de HIV e hepatites virais. A testagem teve como público-alvo pessoas mais vulnerabilizadas às infecções sexualmente transmissíveis, com coleta de amostras de urina e/ou swabs vaginal, endocervical e/ou uretral masculino. Questionários foram enviados aos gestores estaduais e profissionais de laboratório sobre a implantação-piloto. De maneira geral, as avaliações foram positivas. Entre as fraquezas, citou-se dificuldades na mudança do processo de trabalho, carência de recursos humanos, pouca sensibilidade de profissionais da assistência e ausência de tubo primário de urina, único insumo não fornecido. Como fortaleza, destaca-se aquisição centralizada de testes, compartilhamento de equipamentos e armazenamento de amostras à temperatura ambiente. Das 16.177 pessoas testadas, 1.004 (6,21%) foram positivas para C. trachomatis, 1.036 (6,4%) para N. gonorrhoeae e 239 (1,48%) para C. trachomatis/N. gonorrhoeae. A detecção de infecção ocorreu mais em pessoas jovens (≤ 24 vs. > 24 anos) (aOR = 2,65; IC95%: 2,38-2,96), do sexo masculino (aOR = 1,95; IC95%: 1,72-2,21), pardas/pretas (aOR = 1,06; IC95%: 1,05-1,11), na Região Sudeste (aOR = 1,08; IC95%: 1,02-1,13) e em amostras de secreção uretral (aOR = 1,46; IC95%: 1,41-1,52). Os resultados deste estudo demonstraram a importância da disponibilização da testagem em âmbito nacional, os quais subsidiaram a implantação da rede definitiva para detecção de C. trachomatis/N. gonorrhoeae no SUS.


  • Open Access

    Demographic and clinical characteristics of people diagnosed with active sexually transmitted infections among monkeypox cases in Brazil: the 2022 outbreak

    by Isabella Nepomuceno de Souza, Ana Roberta Pati Pascom, Matheus Funke Spinelli, Guilherme Borges Dias, Draurio Barreira, Angélica Espinosa Miranda

    The worldwide monkeypox (mpox) outbreak in 2022 showed a high frequency of sexually transmitted infections (STI). A cross-sectional study was carried out using secondary data from the Brazilian official mpox surveillance systems. A total of 10,169 mpox cases were identified, with a median age of 32 years. Among them, 92.3% were male at birth and 57.5% were men who have sex with other men (MSM). Approximately 11% were diagnosed with STI, including 5.8% with syphilis and 2.5% with genital herpes. Individuals aged from 25 to 34 years, MSM, individuals with HIV-positive status, and those manifesting skin eruptions or penile edema were associated with STI. Laboratory investigation for mpox must be implemented as a priority in STI clinics (especially for MSM) to mitigate neglected cases, ensure appropriate treatments, and prevent misdiagnoses.


  • Open Access

    Brazil's Pivotal Moment in Public Health: Establishing the Interministerial Committee (CIEDDS) for the Elimination of Tuberculosis and Socially Determined Diseases

    by Ethel Leonor Noia Maciel, Mauro Niskier Sanchez, Alda Maria Da Cruz, Draurio Barreira Cravo Neto, Nísia Verônica Trindade Lima

    The Unified Health System (Sistema Único de Saúde, SUS) offers universal systemic healthcare to all citizens resident in Brazil. Unfortunately, the system has also suffered years of underfunding, while Brazil is going through a very particular epidemiological transition, involving a triple challenge in the field of healthcare: at the same time as chronic non-communicable diseases, as well as accidents and violence are important public health issues, so are communicable diseases, still constituting an unacceptable burden on the health system, impacting population health.


  • Open Access

    Rethinking HIV prevention in young people: “hierarchization” or “deinstitutionalization”?

    by Draurio Barreira, Tatianna Meireles Dantas de Alencar

    The paper by Grangeiro et al. 1 1. Grangeiro A, Ferraz D, Magno L, Zucchi EM, Couto MT, Dourado I. HIV epidemic, prevention technologies, and the new generations: trends and opportunities for epidemic response. Cad Saúde Pública 2023; 39 Suppl 1:e00144223. bring to the debate a qualified, contemporary, and timely discussion on the challenges of HIV prevention in young people and on what we mean by “safe sex” after four decades of epidemic. This is a particularly important debate due to the emergence of new preventive technologies in the last decade and a deep sociocultural transformation to the forms of affective, sexual, and substance use interactions by people aged from 15 and 24 years.

  • Open Access

    Repensando a prevenção do HIV entre jovens: hierarquização ou desinstitucionalização?

    by Draurio Barreira, Tatianna Meireles Dantas de Alencar

    O artigo de Grangeiro et al. 1 1. Grangeiro A, Ferraz D, Magno L, Zucchi EM, Couto MT, Dourado I. HIV epidemic, prevention technologies, and the new generations: trends and opportunities for epidemic response. Cad Saúde Pública 2023; 39 Suppl 1:e00144223. traz para o debate uma discussão qualificada, atual e oportuna sobre os desafios da prevenção do HIV entre jovens e sobre o que entendemos por sexo seguro, após quatro décadas de epidemia. É um debate particularmente importante pelo surgimento, nos últimos dez anos, de novas tecnologias preventivas e de uma profunda transformação sociocultural nas formas de interações afetivas, sexuais e de uso de substâncias por jovens entre 15 e 24 anos.